Sanjeevani Bio-tech Exim Private Limited

Sanjeevani Bio-Tech Exim Private Limited (SBEPL) is a privately held pharmaceutical company incorporated on June 9, 2010, in Ahmedabad, Gujarat, India. The company specializes in the export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. As of March 31, 2025, SBEPL reported a total export value of $2.6 million USD across 54 shipments, with a product portfolio concentrated entirely in the Antimalarial & Antiparasitic therapeutic category. The company's registered office is located at D/2004-2009, Sun Central Place, Above Axis Bank, Opposite Iscon Platinum, Ambli, Ahmedabad, Gujarat, 380058, India.

SBEPL operates manufacturing facilities in India, specializing in the production of various pharmaceutical dosage forms, including tablets, capsules, syrups, and injections. The company emphasizes high-quality manufacturing processes to ensure the efficacy and safety of its products. Specific details regarding the locations and capacities of these facilities are not publicly disclosed.

The leadership team at SBEPL comprises:

• Abhinav Bhargava: Director, appointed on October 14, 2011.

• Rajiv Rajendranath Bhargav: Director, appointed on December 21, 2011.

• Ranjana Sanjay Bhargav: Director, appointed on October 14, 2011.

These individuals play pivotal roles in steering the company's strategic direction and operations.

SBEPL's export activities are primarily focused on markets in Asia and South Africa, including countries such as Bangladesh, Yemen, Cambodia, Nigeria, Sudan, the Philippines, Kenya, Somalia, and Dubai. The company has established a global footprint by fulfilling the requirements of clients across these regions. However, specific details regarding regulatory filings, approvals, and market access status in the United States, European Union, United Kingdom, Australia, and Japan are not publicly available.

SBEPL has made significant inroads into emerging markets in Africa, Latin America, and Southeast Asia. The company's products are available in over nine countries, including Nigeria, Kenya, and the Philippines. While the company emphasizes providing affordable quality medicines globally, specific information regarding WHO prequalification or other certifications enabling access to these markets is not publicly disclosed.

SBEPL's export strategy demonstrates a focused approach, primarily targeting markets in Asia and South Africa. This concentration allows the company to leverage regional expertise and establish strong relationships with clients. However, the lack of diversification into other geographic regions may expose the company to risks associated with market fluctuations and regulatory changes in these specific areas.

Specific information regarding SBEPL's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history is not publicly available. The company's export activities are primarily focused on markets in Asia and South Africa, and there is no publicly disclosed evidence of FDA approvals or registrations.

SBEPL emphasizes high-quality manufacturing processes to ensure the efficacy and safety of its products. However, specific details regarding WHO prequalification, EU Good Manufacturing Practice (GMP) certificates, or European Directorate for the Quality of Medicines & HealthCare (EDQM) status are not publicly disclosed.

SBEPL operates under the regulatory framework of the Central Drugs Standard Control Organisation (CDSCO) in India. The company holds manufacturing licenses and approvals from state drug controllers, ensuring compliance with Indian pharmaceutical regulations. Specific details regarding export No Objection Certificates (NOCs) are not publicly available.

As of March 28, 2026, there are no publicly available records of Form 483 observations, warning letters, or import alerts issued to SBEPL by regulatory authorities. The company's operations appear to be in good standing with regulatory bodies.

SBEPL operates in the competitive pharmaceutical export market, focusing on finished pharmaceutical formulations. While specific competitors in overlapping categories are not publicly disclosed, the company's emphasis on high-quality manufacturing and affordable pricing positions it favorably in the market. However, the lack of diversification in its product portfolio and geographic reach may limit its competitive edge compared to more diversified competitors.

SBEPL's key differentiators include its focus on high-quality manufacturing processes and a product portfolio concentrated entirely in the Antimalarial & Antiparasitic therapeutic category. This specialization allows the company to develop expertise and establish a strong presence in this niche market. However, the concentration of its product portfolio may limit its ability to capitalize on opportunities in other therapeutic areas.

SBEPL's current strategic direction appears to be focused on exporting finished pharmaceutical formulations, particularly in the Antimalarial & Antiparasitic category. The company's emphasis on high-quality manufacturing and affordable pricing suggests a commitment to providing accessible healthcare solutions. Future strategic directions may involve diversification of its product portfolio and expansion into new geographic markets to mitigate risks associated with market concentration.

SBEPL has established itself as a reliable supplier in the pharmaceutical export market, with a total export value of $2.6 million USD across 54 shipments. The company's focus on high-quality manufacturing processes and affordable pricing indicates a commitment to meeting the needs of its clients. However, the concentration of its product portfolio and geographic reach may impact the consistency and reliability of its supply chain.

Importers should verify the following certifications when considering SBEPL as a supplier:

• FDA Facility Registration: To ensure compliance with U.S. regulatory standards.

• WHO Prequalification: To confirm adherence to international quality standards.

• EU GMP Certificate: To verify compliance with European manufacturing practices.

• ISO Certification: To assess the company's commitment to quality management systems.

Verification can be conducted through official regulatory bodies or by requesting copies of the certificates directly from SBEPL.

When conducting due diligence on SBEPL, consider the following steps:

• Verify Regulatory Certifications: Ensure the company holds valid certifications from relevant regulatory bodies.

• Assess Financial Health: Review financial statements to evaluate profitability and financial stability.

• Evaluate Supply Chain Reliability: Assess the consistency and reliability of the company's supply chain.

• Review Product Portfolio: Examine the diversity and quality of the company's product offerings.

• Check for Regulatory Compliance: Confirm adherence to local and international regulatory standards.

Red flags to watch for include a lack of diversification in product offerings, limited geographic reach, and absence of certifications from recognized regulatory bodies. Recommended pre-order checks involve verifying the authenticity of certifications and assessing the company's reputation in the market.